AltaCorp Expands Its Research Coverage of Cannabis

Published: October 3, 2018

AltaCorp Expands Its Research Coverage of Cannabis

AltaCorp Capital Inc., a leading capital markets firm, is pleased to announce the addition of David Kideckel as a managing director on the equity research team covering Healthcare and Life Sciences. Kideckel brings almost 20 years of health-related experience to this position and will be based in the firm’s Toronto office.

“The cannabis sector continues to rapidly evolve as Canada moves toward legalization, and with the development of cannabinoid applications in the medical industry, David’s vast knowledge and direct experience in healthcare and biotechnology with both public and private companies make him a significant asset for our clients,” said Jon Horsman, AltaCorp’s Chairman & CEO. “His specialized background is a differentiating factor that will help investors and corporate clients navigate the complex business and regulatory environment that this new industry will face.”

Prior to joining AltaCorp, Kideckel was the director of Healthcare & Biotechnology, Institutional Equity Research, at Beacon Securities Ltd. He has also held senior positions at various pharmaceutical and medical device companies, including Alexion Pharmaceuticals, OtoSim Inc., and Johnson & Johnson. Kideckel graduated from the University of Winnipeg with a Bachelor of Science and Bachelor of Arts in neuropsychology, and has earned a Master of Science from McMaster University, as well as a PhD in neuroscience from the Institute of Medical Science, and a Master of Business Administration from the Rotman School of Management, both at the University of Toronto.

“David’s unique background will combine healthcare and business insights, and will be invaluable to AltaCorp’s growing portfolio of cannabis and life sciences clients,” said Nick Lupick, head of Research. “This year, AltaCorp has raised or advised on over $2 billion of transactions in this sector, so David is an important addition to our team as his expertise will add another dimension to our analysis, turning insights into actionable investment opportunities for our clients.”